Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990

Archives of Neurology

Volumn 63, Issue 2, 2006, Pages 205-209

  Van Gerpen, Jay A ^a   Kumar, Neeraj ^b   Bower, James H ^b   Weigand, Stephen ^b   Ahlskog, J Eric ^b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DYSKINESIA; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PARKINSON DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; UNITED STATES;

AGED; ANTIPARKINSON AGENTS; COHORT STUDIES; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MINNESOTA; PARKINSON DISEASE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 32944466421     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.63.2.205     Document Type: Article

References (29)

1. Rascol O, Brooks D, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484-1491.
2. Schwarz J. Rationale for dopamine agonist use as monotherapy in Parkinson's disease. Curr Opin Neurol. 2003;16(suppl 1):S27-S33.
3. Barone P. Clinical strategies to prevent and delay motor complications. Neurology. 2003;61(suppl 3):S12-S16.
4. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications: results of a double-blind levodopa controlled trial. Drugs. 1998;55(suppl 1):23-30.
5. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000;284:1931-1938.
6. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54:93-101.
7. Bracco F, Battaglia A, Chouza C, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs. 2004;18:733-746.
8. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448-458.
9. Lyons KE, Hubble JP, Troster AI, Pahwa R, Koller WC. Gender differences in Parkinson's disease. Clin Neuropharmacol. 1998;21:118-121.
10. Zappia M, Annesi G, Nicoletti G, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol. 2005;62:601-605.
11. Blanchet PJ, Allard P, Gregoire L, Tardif F, Bedard PJ. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci. 1996;23:189-193.
12. Grandas F, Galiano ML, Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol. 1999;246:1127-1133.
13. Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord. 2005;20:342-344.
14. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology. 1999;52:1214-1220.
15. Cedarbaum JM, Gandy SE, McDowell FH. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias or dementia in Parkinson's disease. Neurology. 1991;41:622-629.
16. Miyawaki E, Lyons K, Pahwa J, et al. Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol. 1997;20:523-530.
17. Maier Hoehn MM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm Suppl. 1983;19:253-264.
18. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord. 1987;2:73-91.
19. Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson's disease revisited: clinical features, natural history, and mortality. Mov Disord. 1998;13:885-894.
20. Muenter MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia ("I-D-I" and "D-I-D-") in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc. 1977;52:163-174.
21. Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol. 1989;25:523-526.
22. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20:190-199.
23. Hiner BC, Earnhart M. Ropinirole as compared with levodopa in Parkinson's disease. N Engl J Med. 2000;343:884-885.
24. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study. Brain. 2000;123:2297-2305.
25. Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D - a generic quality of life measure - is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000;69:67-73.
26. Siderowf A, Ravina B, Glick HA. Preference-based quality-of-life in patients with Parkinson's disease. Neurology. 2002;59:103-108.
27. Zach M, Friedman A, Slawek J, Derejko M. Quality of life in Polish patients with long-lasting Parkinson's disease. Mov Disord. 2004;19:667-672.
28. Marras C, Lang A, Krahn M, Tomlinson G, Naglie G; Parkinson Study Group. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Mov Disord. 2004;19:22-28.
29. Damiano AM, McGrath MM, Willian MK, et al. Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life. Qual Life Res. 2000;9:87-100.